Belite Bio, Inc (BLTE)
$151.87-4.24%Close
SELLBEAR · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $6.1B
- Beta
- -1.23
- P/E (TTM)
- -55.03
- Short % float
- 5.73%
- Days to cover
- 7.3
- SI change
- +0.7%
- 1W
- -2.40%
- 1M
- -12.21%
- vs SPY 1W
- -2.26%
- vs SPY 1M
- -14.72%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 39
- VALUE
- 5
- GROWTH
- 39
- GARP
- 55
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-9.4%
REV YoY-
ROE-15.6%
EPS YoY-
ROA-12.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-55.03
P/E FWD90.46
SECTOR PE20.34
INDUSTRY PE13.84
P/B7.86
P/FCF-
EV/EBITDA-53.30
EV/EBIT-
PEG0.66
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO33.56
ND/EBITDA-
BETA-1.23
Company news
FAQ
- What is LOPJLB’s current signal on BLTE?
- LOPJLB’s latest quantitative signal on Belite Bio, Inc (BLTE) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is BLTE in?
- Belite Bio, Inc (BLTE) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Belite Bio, Inc (BLTE) do?
- Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical tria…